Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy
using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells.
Giving lapatinib together with tamoxifen may be an effective treatment for breast cancer.
PURPOSE: This randomized phase I trial is studying the side effects of lapatinib and
tamoxifen in treating patients with advanced or metastatic breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC